MOTS-c Peptide Interacts with Bcl-2 to Combat Fatty Liver Disease
Background
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by liver inflammation, hepatocyte damage, and fibrosis, often progressing to cirrhosis and liver failure. Current treatments are limited, and the complex mechanisms underlying its progression, especially involving mitochondrial dysfunction, are not fully understood. This study addresses the knowledge gap regarding the role of mitochondrial-encoded peptides like MOTS-c in modulating key cellular pathways to alleviate NASH progression.
Results
The study revealed that MOTS-c treatment significantly attenuated NASH progression in the mouse model. Treated mice showed a 43% reduction in hepatic triglyceride accumulation compared to controls (p<0.001), along with a 35% decrease in liver inflammation scores as measured by histological analysis. Furthermore, MOTS-c significantly lowered circulating ALT and AST levels by 55% and 48% respectively (p<0.01), indicating improved liver function and reduced hepatocyte injury. > MOTS-c treatment led to a remarkable 60% reduction in liver fibrosis markers (e.g., α-SMA, collagen I) and a 2.5-fold increase in anti-apoptotic Bcl-2 expression in hepatocytes, demonstrating its direct protective mechanism against cell death. In vitro studies confirmed that MOTS-c directly binds to Bcl-2, enhancing its anti-apoptotic activity and protecting hepatocytes from lipotoxicity-induced cell death by 30%.
Why It Matters
This research highlights MOTS-c as a novel and potent regulator of NASH progression, acting through a direct interaction with Bcl-2 to mitigate hepatic steatosis, inflammation, and fibrosis. The findings underscore the therapeutic potential of targeting mitochondrial pathways for complex metabolic diseases, offering a new mechanistic understanding. This research opens avenues for developing MOTS-c as a novel therapeutic strategy for NASH patients, offering a new hope for a condition with limited treatment options. Future studies should focus on validating these findings in larger animal models and eventually progressing to human clinical trials (Phase II) to assess safety and efficacy.